{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_2",
        "name": "Tetrathiomolybdate Washout Period",
        "type": "Before",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Experimental Therapy Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_4",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_5",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_6",
        "name": "Enrollment",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_7",
        "name": "CRU Admission Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "CRU Discharge Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "CRU Re-admission Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_10",
        "name": "Outpatient Period Extension",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_11",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_12",
        "name": "Dose Titration Timing",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_13",
        "name": "SRC Safety Review",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_14",
        "name": "Post-Dose Fasting",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_15",
        "name": "Pre-Dose Fasting",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_16",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_17",
        "name": "Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "ALT/AST Elevation (Moderate)",
        "instanceType": "Condition",
        "description": "Alanine or Aspartate aminotransferase elevation greater than 3 times and less than or equal to 5 times the upper limit of normal.",
        "text": "ALT/AST > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_2",
        "name": "ALT/AST Elevation (Severe)",
        "instanceType": "Condition",
        "description": "Alanine or Aspartate aminotransferase elevation greater than 5 times the upper limit of normal.",
        "text": "ALT/AST > 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "Hemoglobin Decrease",
        "instanceType": "Condition",
        "description": "Clinically significant decrease in hemoglobin from baseline.",
        "text": "> 2 g/dL ↓ from baseline"
      },
      {
        "id": "cond_4",
        "name": "Platelet Decrease",
        "instanceType": "Condition",
        "description": "Clinically significant decrease in platelets from baseline.",
        "text": "> 30% ↓ from baseline"
      },
      {
        "id": "cond_5",
        "name": "Neutrophil Decrease",
        "instanceType": "Condition",
        "description": "Clinically significant decrease in neutrophils from baseline.",
        "text": "> 30% ↓ from baseline and neutrophils below reference range"
      },
      {
        "id": "cond_6",
        "name": "Potential Liver Injury",
        "instanceType": "Condition",
        "description": "Elevated bilirubin accompanied by elevated ALT, indicative of potential liver injury.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN"
      },
      {
        "id": "cond_7",
        "name": "Neurological Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening by Adverse Events or by neurologic physical exam assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis.",
        "text": "Evidence of clinically significant acute psychiatric worsening"
      },
      {
        "id": "cond_9",
        "name": "Safety Concerns Pre-Titration",
        "instanceType": "Condition",
        "description": "Safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk for dose titration.",
        "text": "Safety concerns that may place participants at undue risk"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "On Day 29, increase dose from 15 mg/day to 30 mg/day, unless there are safety concerns. SRC to review safety data through Day 23 prior to titration."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT/AST > 3x ULN and <= 5x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Severe ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT/AST > 5x ULN, discontinue study intervention."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Abnormalities",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin, Platelets, or Neutrophils decrease beyond threshold, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN with ALT > 3x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic/Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Upon neurologic or psychiatric worsening, Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease)."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Serious Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for a serious hypersensitivity reaction."
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Severe Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for a severe uncontrolled infection."
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for use of disallowed medication."
      },
      {
        "id": "trans_10",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor or Investigator Study Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "The study site or entire study may be closed early by Alexion or the Investigator for reasons such as non-compliance, inadequate recruitment, or discontinuation of study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 29 to titrate dose from 15 mg/day to 30 mg/day, based on SRC review of safety data through Day 23.",
        "conditionIds": [
          "cond_9"
        ]
      },
      {
        "id": "dec_2",
        "name": "Liver Safety Dose Modification",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing monitoring of liver function tests to determine if dose modification (interruption or discontinuation) is required.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_6"
        ]
      },
      {
        "id": "dec_3",
        "name": "Hematology Safety Dose Modification",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing monitoring of complete blood count to determine if dose reduction is required.",
        "conditionIds": [
          "cond_3",
          "cond_4",
          "cond_5"
        ]
      },
      {
        "id": "dec_4",
        "name": "Neurologic and Psychiatric Safety Dose Modification",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing monitoring for neurologic or psychiatric worsening to determine if dose modification is required.",
        "conditionIds": [
          "cond_7",
          "cond_8"
        ]
      }
    ],
    "summary": {
      "timingCount": 17,
      "conditionCount": 9,
      "transitionRuleCount": 10,
      "exitCount": 5
    }
  }
}